ReviewCancers2023
Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Liver transplantation as a new treatment option for perihilar cholangiocarcinoma and colorectal liver metastases: a review.International journal of clinical oncology · 2026Review
- Pulmonary Metastasectomy After Liver Transplantation: Indications, Timing, and Surgical Decision-Making Across Primary Tumor Histologies.Diagnostics (Basel, Switzerland) · 2026Review
- Revisiting treatment paradigms for colorectal liver metastases: liver transplant or associating liver partition and portal vein ligation for staged hepatectomy?Hepatobiliary surgery and nutrition · 2026Article
- Article
- Current perspectives and guidelines on liver transplantation for metastatic colorectal cancer.World journal of transplantation · 2025Review
- Navigating the complexity of colorectal liver metastasis: molecular profiling and tumor sidedness.Hepatobiliary surgery and nutrition · 2025Article
- Expanding Indications in Transplant Oncology.Cancers · 2025Review
- Mid-transversal hepatectomy: breaking new ground in parenchymal sparing hepatectomies.Updates in surgery · 2025Article
- The evolving role of liver transplantation for metastatic colorectal cancer: current perspectives and future directions.Frontiers in surgery · 2025Review
- Rescue liver transplantation for post-hepatectomy liver failure- single center retrospective analysis.BMC surgery · 2024Article
- Liver Transplantation for Unresectable Colorectal Liver Metastasis: Perspective and Review of Current Literature.Current oncology (Toronto, Ont.) · 2024Review
- Update to 'A Contemporary Systematic Review on Liver Transplantation for Unresectable Liver Metastasis of Colorectal Cancer'.Annals of surgical oncology · 2024Article
- Using machine learning approach for screening metastatic biomarkers in colorectal cancer and predictive modeling with experimental validation.Scientific reports · 2023Article
- The Role of Liver Transplantation in the Treatment of Liver Metastases from Neuroendocrine Tumors.Current treatment options in oncology · 2023Review
- Extracellular Vesicles in Liver Transplantation: Current Evidence and Future Challenges.International journal of molecular sciences · 2023Review
- Article
- Liver transplantation for non-resectable colorectal metastases-an evolving paradigm in transplant oncology.Hepatobiliary surgery and nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
More than 40% of patients with colorectal cancer present liver metastases (CRLM) during the course of their disease and up to 50% present with unresectable disease. Without surgical interventions, survival for patients treated with systemic therapies alone is dismal. In the past, liver transplantation (LT) for patients with unresectable CRLM failed to show any survival benefit due to poor selection, ineffective chemotherapeutic regimens, unbalanced immunosuppression and high perioperative mortality. Since then and for many years LT for CRLM was abandoned. The turning point occurred in 2013, when the results from the Secondary Cancer (SECA I) pilot study performed at Oslo University were published reporting a 60% 5-year overall survival after LT in patients with unresectable CRLM. These results effectively reignited the interest in LT as a potential therapy for CRLM, and several trials are undergoing. The aims of this article are to give a comprehensive overview of the available evidence on LT for CRLM, discuss the open issues in this rapidly evolving field, and highlight possible ways to address the future of this fascinating therapeutic alternative for selected patients with CRLM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.